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In The Lancet, Richard McManus and colleagues1 in the 
TASMINH4 trial address a timely and clinically relevant 
question, as to whether self-monitoring of blood 
pressure, with or without telemonitoring, when used by 
general practitioners (GPs) to titrate antihypertensive 
therapy in individuals with poorly controlled blood 
pressure, leads to significantly lower blood pressure than 
titration guided by clinic readings alone. 
In their unmasked, randomised controlled trial in 
142 UK general practices, hypertensive patients older 
than 35 years taking no more than three antihypertensive 
agents with blood pressure higher than 140/90 mm Hg 
were assigned to self-monitoring using an automated 
electronic sphygmomanometer (n=395), telemonitoring 
with patients sending blood pressure readings via a 
simple free SMS text-based telemonitoring service with 
web-based data entry back-up (n=393), or to usual care 
(n=394). 1003 (85%) of these patients were included in 
the primary analysis and the primary outcome was clinic 
measured systolic blood pressure at 12 months from 
randomisation. Compared with usual care, the decrease 
in clinic measured systolic blood pressure at 12 months 
in patients in both self-monitoring groups was clinically 
meaningful (self-monitoring 137·0 [SD 16·7] mm Hg 
and telemonitoring 136·0 [16·1] mm Hg vs usual care 
140·4 [16·5] mm Hg; adjusted mean differences vs 
usual care: self-monitoring alone –3·5 mm Hg [95% CI 
–5·8 to –1·2]; telemonitoring –4·7 mm Hg [–7·0 to –2·4]). 
If sustained, such reductions in blood pressure could be 
expected to reduce stroke risk by 20% and coronary heart 
disease risk by 10%.
These results might seem unsurprising, but it is easy 
to forget that we lack a critical mass of random ised data 
showing whether correctly implemented self-monitoring, 
generating results on which physicians will titrate therapy, 
can result in better blood pressure control.2 As such, these 
results are important and reassuringly validate current 
clinical practice, as already applied to many individuals 
with hypertension worldwide.3 Although certainly not yet 
the norm, increasingly in many practices, patients bring 
in a more or less structured set of self-monitored blood 
pressure measurements on which physicians often base 
their therapeutic actions.
According to McManus and colleagues, it is the 
differential intensification by the GPs of antihypertensive 
medication in response to the patients’ input signals of 
self-monitored blood pressure that is the mechanism 
involved in the better blood pressure decrease in the self-
monitoring groups—an effect that requires the action, 
time, and attention of a medically trained individual. 
But does it need to be so? It should be noted that in the 
TASMINH24 and TASMIN-SR5 trials using telemonitoring 
and self-titration by the patient, the blood pressure drop 
was of roughly similar magnitude as in this trial.
There are some limitations to this otherwise 
excellent trial. First, the trial was designed before 
starting with combination antihypertensive therapy 
was the norm.6 It is a matter of debate whether 
blood pressure reductions would be successful to 
the same degree if GPs had to start their efforts in 
patients with poorly controlled blood pressure who 
were using more than two or three antihypertensive 
drugs. Second, would addition of ambulatory blood 
pressure data—left out for reasons of feasibility—have 
yielded additional insights? Third, the addition of 
telemonitoring in this trial on top of self-monitoring 
resulted in a non-significantly larger but more rapid 
decrease in blood pressure. The by-design unobtrusive 
nature of the intervention (SMS reminders to measure 
blood pressure and a fairly easy way to present 
results and alerts to the GP and patient) might have 
nullified a potential significant effect. Blood pressure 
control could have benefited from a more stringent 
and compulsory telemonitoring-aided intervention 
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urging both patient and GP towards a next mandatory 
step-up in therapy.
Thus, in the TASMINH41 study the physician was in the 
driver’s seat to either ignore the patient’s input signal 
or to re-evaluate the installed therapy. This approach 
seemed to work, although it is questionable whether this 
strategy will remain equally effective in the foreseeable 
future when doctors get overwhelmed by a deluge of 
such digital health signals.
With increasing use of digital medicine, physicians are 
facing the early stages of a change in clinical practice, 
ranging from emails and social media messages 
from patients to automatically transmitted data from 
a plethora of wearables or connected point-of-care 
devices (eg, for blood pressure, glycaemia, N-terminal 
pro b-type natriuretic peptide, heart rhythms, and 
therapeutic drug monitoring) or from implantable 
devices (eg, defibrillators and pacemakers), which will 
be transmitted to doctors (including GPs) for medical 
advice, with expectations of direct medical scrutiny 
and therapeutic reactions if required.7 Although these 
changes are useful for advancing daily clinical practice 
and likely beneficial for the patients, this massive inflow 
of data, often using proprietary formats and requiring 
separate dedicated (manufacturer-specific) software 
platforms, is already starting to put a strain on the 
medical community. In many countries and health-
care systems, there is neither clear technical regulatory 
guidance for e-health interventions nor properly defined 
legal responsibilities. Moreover, the necessary structural 
reimbursement or person power to support doctors is 
lacking in most settings.
Surely, it is time for care providers to rethink the chain 
of medical decision taking in hypertension management? 
Should not the driver’s seat be co-chaired by health 
literate patients and dedicated professionals from allied 
fields? Could it be a valuable option to empower patients 
whenever possible, introducing them to self-titration and 
self-initiation of antihypertensive drug therapy? Such an 
option would be controversial and not devoid of risks but 
could be a worthwhile and future-proof strategy.8
In 2016, the Lancet Commission on hypertension8 
launched “A call to action and a lifecourse strategy to 
address the global burden of raised blood pressure on 
current and future generations” that aimed to move 
beyond the current stalemate. Among other key actions, 
education (of patients, doctors, and the general public), 
empowerment, and expansion of the workforce engaged 
in the management of blood pressure through task 
sharing were seen as central.
A feasible future scenario could be GPs acting as 
highly educated central health-care managers who 
not only treat individual patients but also orchestrate 
community health through a digital infrastructure, 
designed in conjunction with the medical end-user 
and relying on dedicated artificial intelligence. This 
forward-looking strategy could be equally applicable to 
middle-income and low-income countries where there 
is often a shortage of physicians and a high burden of 
untreated and undiagnosed hypertension—a driver’s 
seat allowing doctors to efficiently achieve both clinical 
and population outcomes. This should not be viewed as 
an abdication of responsibility but as an embracing of a 
far more wide-ranging collective responsibility.
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